Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. EPS / Forecast. All times are ET. ... Yearly Earnings Forecast ... basis and include stock option expenses where possible. SCYNEXIS, Inc. (NASDAQ:SCYX) SCYNEXIS, Inc. (NASDAQ:SCYX) is a biotech firm based in New Jersey. 02/02 13:28. Invasive Aspergillosis. Home. View XFOR's stock price, price target, earnings, financials, forecast, insider trades, news, and SEC filings at MarketBeat. Specifically, all four covering analysts recommend buying the shares. Clinical Trials. 1. The SCYNEXIS PE ratio based on its reported earnings over the past 12 months is null. 60-Month Beta: Coefficient that measures the volatility of a stock's returns relative to the market (S&P 500). Scynexis Data Show Brexafemme Prevents VVC Recurrence 10 Feb 2022 Lilly/Innovent Experience Show Hurdles Remaining For Chinese PD-1 Inhibitors 10 Feb 2022 Biogen's Aduhelm Defense Highlights Therapeutic Area Discrepancies 10 Feb 2022 Quite a few analysts cover the stock, so you could look into forecast growth quite easily. Bullish Descending Wedge. Our lead asset, ibrexafungerp (formerly known as SCY-078), is a broad-spectrum, IV/oral antifungal agent representing a novel therapeutic class. SCYX Stock Analysis - [Full Report] SCYX Chart by TradingView. Friday, March 27, 2020. Insider Ownership Of SCYNEXIS The definition of an insider can differ slightly between different countries, but members of the board of directors always count. Science. SCYX Stock Analysis - [Full Report] SCYX Chart by TradingView. Get a free SCYX technical analysis report to make a better Scynexis stock predictions on how the stock will perform in the near future. Clinical Trials. SCYNEXIS Reports Inducement Grants Under Nasdaq … Never … In a nutshell, if Scynexis' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. Scynexis stock price target cut to $16 from $22 at Maxim Group. SCYNEXIS in a strong financial position to execute on its plans with a projected cash runway into 2023. Scynexis. 36.92% of the stock of SCYNEXIS is held by institutions. TD Ameritrade displays two types of stock earnings numbers, which are calculated differently and may report different values for the same period. The current SCYNEXIS Inc [ SCYX] share price is $4.81. The stock options and RSUs were granted as material inducements to the new employees to accept SCYNEXIS’ offers of employment. Scynexis Inc. (NQ: ) 4.750 USD -0.050 (-1.05%) Streaming Delayed Price 4:00:01 PM EST, Jan 26, 2022 Add to My Watchlist. We would highlight that SCYNEXIS' revenue growth is expected to slow, with the forecast 42% annualised growth rate until the end of 2022 being well below the historical 86% p.a. The average twelve-month price target for SCYNEXIS is $25.67 with a high price target of $35.00 and a low price target of $20.00. Goldman ups Fed hike forecast to 7 rate increases in 2022 after CPI data Zillow (ZG) Stock Soars 13% on Strong Beat, Analyst Impressed by … For several months, analysts have been revising their EPS estimates roughly upwards. Scynexis (NASDAQ: SCYX) stock has been battered in the past year as the stock price has dropped by 22.5%. SCYX updated stock price target summary. Dublin, Feb. 09, 2022 (GLOBE NEWSWIRE) -- The "Global Antifungal Agents Market 2021-2027" report has been added to ResearchAndMarkets.com's offering. We'd be curious to see if the downgrade is enough to reverse investor sentiment on the business. Investors can use this forecasting interface to forecast Scynexis historical stock prices and determine the direction of Scynexis's future trends based on various well-known forecasting models. Never … SCYX 5.11 0.06 (1.16%) Post-Market 0.01 (0.20%) 10,404. Scynexis' implied volatility exposes the market's sentiment of Scynexis stock's possible movements over time. -0.06 / -0.725. SCYNEXIS, Inc., a biotechnology company, delivers therapies for the treatment fungal infections in the United States. Please note that any opinions, estimates or forecasts regarding SCYNEXIS, Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts … stock forecast and half had a lower SCYNEXIS,. Scynexis stock price target cut to $15 from $40 at Maxim Group MarketWatch. It is also a measure of investors' predictions about future volatility of the underlying stock. Research. The pandaforecast.com portal is not responsible for the loss of your money in the stock market as a result of using the information contained on the site. The grants consisted of stock options to purchase an aggregate of 41,000 shares of SCYNEXIS common stock at a per share exercise price of $4.90, the closing trading price on January 31, 2022, and 16,000 RSUs. Get the latest SCYNEXIS, Inc. SCYX detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Globe Newswire. Quarterly Reports Insider Filings Other Filings. Get a free SCYX technical analysis report to make a better Scynexis stock predictions on how the stock will perform in the near future. It is based on a 60-month historical regression of the return on the stock onto the return on the S&P 500. SCYX is currently trading in the 40-50% percentile range relative to its historical Stock Score levels. Overview Detailed Quote Charting Historical Prices. According to the issued ratings of 4 analysts in the last year, the consensus rating for SCYNEXIS stock is Buy based on the current 4 buy ratings for SCYX. SCYNEXIS Inc (SCYX) Stock Analysis: Based on the SCYNEXIS Inc stock forecasts from 0 analysts, the average analyst target price for SCYNEXIS Inc is not available over the next 12 months. MT Newswires. Michael Burry slashed his US stock portfolio in the third quarter. If you had invested in Scynexis stock at $90.00, your return over the last 7 years would have been -94.26%, for an annualized return of -33.51% (not including any dividends or dividend reinvestments). Scynexis said this trial was conducted under a special protocol assessment, a process in which sponsors work with the FDA to reach agreement on the design and size of a clinical trial to adequately address scientific and regulatory requirements for a study that could support marketing approval. Still, this is double the stock's annual high of $5.51, and most of Wall Street is, for now, behind SCYNEXIS Inc. SCYNEXIS, Inc., a biotechnology company, delivers therapies for the treatment fungal infections in the United States. IV can help traders determine if options are fairly valued, undervalued, or overvalued. SCYX Stock Predictions, Articles, and Scynexis Inc News From the Web Scynexis Presents Interim Ibrexafungerp Data In Hospital-Based Fungal Infections Date Range. You will never again be left in the dark on when a stock moves. Latest Release. GAAP earnings are the official numbers reported by a company, and non-GAAP earnings are adjusted to be more readable in earnings history and forecasts. Get SCYNEXIS Inc (SCYX:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. The average price target is $19.50 with a high forecast of $22.50 and a low forecast of $16.00. SCYNEXIS to Participate in Upcoming January Investor Conferences. New consensus forecast suggests the company will make a profit of US$36.0m in 2024. The prediction is based on 6 analyst estimates. PR Newswire -6.09%. SCYNEXIS Inc’s average analyst rating is not available. It is calculated by dividing a company's price per share by its earnings per share. Their forecasts range from $20.00 to $35.00. On average, they expect SCYNEXIS's stock price to reach $25.50 in the next twelve months. This suggests a possible upside of 370.5% from the stock's current price. View analysts' price targets for SCYNEXIS or view top-rated stocks among Wall Street analysts. Who are SCYNEXIS's key executives? When using the forecast data, the investor assumes all financial risks. The past five years for SCYNEXIS (NASDAQ:SCYX) investors has not been profitable. However, solely looking at the historical price movement is usually misleading. Analyst Coverage. Tuesday, July 21, 2020. That means the average analyst price target for SCYX stock is $24.92. Average annual earnings growth of 64% is required to achieve expected profit on schedule. The SCYX stock forecast is provided by MarketClub with their Trade Triangle system. All statements and expressions are the sole opinion of the company and are subject to change without notice. 02/03 16:15. In comparing SCYNEXIS Inc. (SCYX)’s stock with other industry players reveals that stock’s current price change of 10.60% and that of -23.32% over the past 12 months is in competing position with that of Galmed Pharmaceuticals Ltd. (GLMD) which saw its stock price fall by -1.84% in the last trading and went through a decrease of -55.43% in past 12-month trading. The global antifungal agents market is estimated to grow at a significant CAGR of nearly 3.5% during the forecast period The rise in the prevalence of infections such as aspergillosis and candidiasis has been … Current Stock Price for SCYNEXIS (SCYX)? Invasive Aspergillosis. A The stock price for SCYNEXIS ( NASDAQ : SCYX ) is $ 7.43 last updated Fri Nov 26 2021 18:00:03 GMT+0000 (Coordinated Universal Time) . SCYNEXIS Announces Closing of $35 Million Public Offering of Common Stock and Warrants. Science. Short-term (time horizon: 2 weeks) SCYNEXIS INC share price prediction for … - Try Now Risk-Free - Money-back guarantee! With upcoming catalysts, such as the first FDA approval for their ibrexafungerp antifungal in Q1 2021 and other catalyst announcements potentially in Q4 2020, this looks prime for a large break out over $10. Forecasting stocks, rates of world currencies and cryptocurrencies using neural networks based on historical data. Find the latest Scynexis Inc (SCYX) stock price forecast, 12-month price target, predictions and analyst recommendations. The stock was halted at $5.20 in premarket trading. SCYNEXIS Inc (SCYX:NMQ) forecasts: consensus recommendations, research reports, share price forecasts, dividends, and earning history and estimates. Quote. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. About the SCYNEXIS, Inc. stock forecast. In their sales forecast, analysts sound optimistic with regard to sales prospects. In the short term (2weeks), SCYX's stock price should underperform the market by -2.07%.During that period the price should oscillate between -11.03% and +12.32%.. However, it does not forecast the overall direction of its price. SCYNEXIS has a twelve month low of $4.90 and a twelve month high of $10.25. Today 200 Day Moving Average is the resistance level (6.63 $). Scynexis Inc Stock Forecast, "SCYX" Stock Predictons by days: 2021. View SCYNEXIS, Inc. SCYX investment & stock information. While not a mind-blowing move, it is good to see that the SCYNEXIS, Inc. (NASDAQ:SCYX) share price has gained 10% in the last three months. SCYNEXIS Research Platform. Dec-12-19 12:46PM. SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. Analysts have a positive opinion on this stock. Should I buy or sell SCYX? Volume today is 59,279 compared to average volume of 61,609. SCYNEXIS, INC. : Forcasts, revenue, earnings, analysts expectations, ratios for SCYNEXIS, INC. Stock | SCYX | US8112922005 Find the latest Hologic, Inc. (HOLX) stock quote, history, news and other vital information to help you with your stock trading and investing. Ibrexafungerp Development Pipeline. Scynexis Inc (SCYX) shares closed today 10.6% higher than it did at the end of yesterday. (NASDAQ: SCYX) Scynexis's current Earnings Per Share (EPS) is -$4.06. on SCYX's analyst rating history. This is even as the company has delivered positive news regarding its drugs. Analyst Predictions. SCYX SCYNEXIS — Stock Price and Discussion | Stocktwits. Should I buy or sell SCYX? Specifically, they have bought $313,750.00 in company stock and sold $4,003,110.00 in company stock. Revenue / Forecast. SCYNEXIS INC stock price forecast for further price development up to 0.02% (time horizon: 1 day) and price target of 5.02 USD. SCYX Stock Predictions, Articles, and Scynexis Inc News From the Web Scynexis Presents Interim Ibrexafungerp Data In Hospital-Based Fungal Infections Scynexis stock price target raised to $22 from $17 at Maxim Group MarketWatch. SCYNEXIS stock forecasts are adjusted once a day based on the closing price of the previous trading day. Refractory Invasive Fungal Infections. The average price target represents a 293.94% change from the last price of $4.95. Yahoo. It is calculated by dividing a company's price per share by its earnings per share. ET by Tomi Kilgore. Find out now with a free analysis on Scynexis. Start your FREE 14-day trial of Benzinga Pro today. 05:30 AM ET. A look at the shareholders of SCYNEXIS, Inc. ( NASDAQ:SCYX ) can tell us which group is most powerful. SCYNEXIS, Inc. (NASDAQ:SCYX) posted its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.79) by $0.73. SCYNEXIS Inc. analyst ratings, historical stock prices, earnings estimates & actuals. Find the latest Scynexis Inc (SCYX) stock price forecast, 12-month price target, predictions and analyst recommendations. What is SCYX's Earnings Per Share (EPS) forecast for 2022-2024? 60-Month Beta: Coefficient that measures the volatility of a stock's returns relative to the market (S&P 500). The minimum target price for SCYNEXIS analysts is $ 23.5. Find market predictions, SCYX financials and market news. Ibrexafungerp Development Pipeline. Learn more. What this means: Scynexis Inc (SCYX) gets an Overall Rank of 60, which is an above average rank under InvestorsObserver's stock ranking system. SCYX has been consolidating into this bullish wedge for months now. Nov 10, 2021. Find real-time SCYX - SCYNEXIS Inc stock quotes, company profile, news and forecasts from CNN Business. Get Our PREMIUM Forecast Now, from ONLY $8.49! Based on SCYX analyst price targets, SCYX stock forecast is $24.92 (for a year from now). The company has a debt-to-equity ratio of 1.05, a quick ratio of 7.81 and a current ratio of 7.86. SCYX Stock Analysis Overview. SCYX stock forecast Our latest prediction for Scynexis Inc's stock price was made on the Dec. 21, 2020 when the stock price was at 6.20$.. Investors should also take note that the median SCYNEXIS,. The shares last closed at $4.95. Monday, January 25, 2016. SCYNEXIS, Inc. is headquartered in Durham, North Carolina. You’ll have what you need to act in real-time — before the crowd. SCYNEXIS, Inc. is followed by the analysts listed above. It is developing its lead product candidate, ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. Stocks Option prices for Scynexis Inc with option quotes and option chains. In the past three months, SCYNEXIS insiders have sold 1,175.89% more of their company’s stock than they have bought. Get the latest news and real-time alerts from SCYNEXIS, Inc. (SCYX) stock at Seeking Alpha. Since the longterm average is above the short-term average there is a general sell signal in the stock giving a more negative forecast for the stock. Scynexis Stock Forecast is based on your current time horizon. Most stock quote data provided by BATS. We are pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant. Target price, charts. Analyst Price Target on SCYX. Our overall hedge fund sentiment score for SCYX is 41.8. The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. Find the latest SCYNEXIS, Inc. SCYX analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports. Find out now with a free analysis on Scynexis. SCYNEXIS Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) JERSEY CITY, N.J., Feb. 03, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant fungal infections, today announced grants of stock options and Restricted Stock Units (“RSUs”) … Scan for strong stocks. Growth remains a strong point in this company. Key Data. Free Signup: Advanced stock screener. JERSEY CITY, N.J., Aug. 02, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant fungal infections, today announced grants of stock options to five new employees to purchase an aggregate of 24,500 shares of SCYNEXIS … SCYX. 4 Wall Street analysts have issued 12 month price targets for SCYNEXIS's stock. Find the latest Earnings Report Date for SCYNEXIS, Inc. Common Stock (SCYX) at Nasdaq.com. Find out if you should buy SCYX stock. The stock has traded between $4.90 and $5.32 so far today. As of 2022 January 26, Wednesday current price of SCYX stock is 4.750$ and our data indicates that the asset price has been in a downtrend for the past 1 year (or since its inception).. Scynexis stock price has been showing a declining tendency so we believe that similar market segments were not very popular in the given … The SCYX stock forecast is provided by MarketClub with their Trade Triangle system. SCYNEXIS, Inc., a biotechnology company, delivers therapies for the treatment fungal infections in the United States. SCYX stock opened at $5.27 on Wednesday. Our system considers the available information about the company and then compares it to all the other stocks we have data on to get a percentile-ranked value. "The Big Short" investor has been warning of a devastating market crash for months. Publications and Presentations. Find out if you should buy SCYX stock. SCYNEXIS Inc Stock Forecast. Scynexis' implied volatility exposes the market's sentiment of Scynexis stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Scynexis' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. Given the current short-term trend, the stock is expected to fall -9.66% during the next 3 months and, with a 90% probability hold a price between $4.05 and $6.46 at the end of this 3-month period. It is based on a 60-month historical regression of the return on the stock onto the return on the S&P 500. Scynexis is a company that is developing medicines to help patients overcome and prevent drug-resistant and difficult-to-treat infections. Scynexis Inc. Stock Predictons by days: 2021. Free Signup: Advanced stock screener. US Stock Forecast. It is developing its lead product candidate, ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. SCYX Stock Forecast - Is SCYX a buy or sell? Today SCYX ranks #906 as buy candidate. Get a Free Stock at Robinhood HC Wainwright is very positive about SCYX and gave it a "Buy" rating on Jun 30, 2021. The price target was set to $20.00. The stock lies in the lower part of a very wide and strong rising trend in the short term, and this may normally pose a very good buying opportunity. Vulvovaginal Candidiasis. --Maxim Group Adjusts SCYNEXIS Price Target to $11 From $16, Maintains Buy Rating. This suggests a possible upside … 09:25 AM ET. The SCYNEXIS stock holds a buy signal from the short-term moving average; at the same time, however, the long-term average holds a general sell signal. The latest earnings per stock, revenues and financial reports for Scynexis Inc (SCYX). In that particular session, Stock kicked-off at the price of $7.00 while reaching the peak value of $7.0599 and lowest value recorded on the day was $6.53. Disclaimer. After the downgrade, the six analysts covering SCYNEXIS are now predicting revenues of US$20m in 2022. WARNING: Trend forecast is still in the development phase and should be used with caution. At the end of the latest market close, SCYNEXIS Inc. (SCYX) was valued at $7.49. Forecast to breakeven in 2024. Invasive Candidiasis. Vulvovaginal Candidiasis. No significant news for in the past two years. The Company is not liable for any investment decisions by its readers or subscribers. SCYNEXIS Research Platform. Wall Street Stock Market & Finance report, prediction for the future: You'll find the Scynexis share forecasts, stock quote and buy / sell signals below.According to present data Scynexis's SCYX shares and potentially its market environment have been in bearish cycle last 12 months (if exists). Coronavirus Pandemic Delays Testing of New Drugs The Wall Street Journal Interactive Edition. SCYNEXIS, INC. : Forcasts, revenue, earnings, analysts expectations, ratios for SCYNEXIS, INC. Stock | SCYX | US8112922005 All quotes are in local exchange time. Q3 2021 SCYNEXIS Inc Earnings Release - Actual: -$0.02; 08/16/21 Q2 2021 SCYNEXIS Inc Earnings Release - Actual: $0.06; 05/17/21 Q1 2021 SCYNEXIS Inc Earnings Release - Actual: -$0.18; 03/29/21 Q4 2020 SCYNEXIS Inc Earnings Release - Actual: -$3.53; More calendar events Exploring X4 Pharmaceuticals (NASDAQ:XFOR) stock? Is SCYNEXIS Inc Stock Undervalued? Publications and Presentations. In the medium term (3months), SCYX's stock price should … Top 3 Stock Picks of Michael Burry. See SCYNEXIS, Inc. (SCYX) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. SCYNEXIS Inc (NASDAQ:SCYX) is not the most popular stock in this group but hedge fund interest is still above average. stock was originally listed at a price of $90.00 in May 2, 2014. Refractory Invasive Fungal Infections. On average, they anticipate SCYNEXIS's share price to reach $25.67 in the next year. What is SCYX stock forecast (i.e., prediction)? The average Scynexis stock price prediction forecasts a potential upside of 576.98% from the current SCYX share price of $5.17. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. SCYNEXIS grants stock options and RSUs to five new employees Seeking Alpha 2/3/2022. The Score for SCYX is 41, which is 18% below its historic median score of 50, and infers higher risk than normal. The SCYNEXIS PE ratio based on its reported earnings over the past 12 months is null. SCYNEXIS Inc (SCYX) stock is trading at $5.23 as of 2:50 PM on Tuesday, Sep 15, a gain of $0.37, or 7.61% from the previous closing price of $4.86. The shares last closed at $6.66. aaronsmth5 Nov 2, 2020. Price/Sales: Latest closing price divided by the last 12 months of revenue/sales per share. News. The stock price has risen 4.6% to US$4.81 over the past week. 52wk High 10.25. 01/20 10:13. Scan for strong stocks. SCYNEXIS NASDAQ Updated Feb 11, 2022 12:07 AM. View live SCYNEXIS, Inc chart to track its stock's price action. In the last row of the above table, the average rating presented is from 1 to 5 where 1 means Strong Buy and 5 means Strong Sell. Only 4.06% of the stock of SCYNEXIS is held by insiders. Based on 3 Wall Street analysts offering 12 month price targets for SCYNEXIS in the last 3 months. Price/Sales: Latest closing price divided by the last 12 months of revenue/sales per share. Over the last twelve months, the sales forecast has been frequently revised upwards. stock forecast price target (i.e. Besides McCarthy, two other analysts are also bullish on the stock, which has a Strong Buy consensus rating. Their forecasts range from $20.00 to $35.00. Scynexis Inc () Stock Market info Recommendations: Buy or sell Scynexis stock? SCYX Stock Forecast - Is SCYX a buy or sell? Positive news sentiment. The stock has a market cap of $151.60 million, a PE ratio of -1.43 and a beta of 1.95. Nov. 17, 2021 at 8:50 a.m. The stock current value is $6.77.Recently in News on December 2 52wk Low 4.21. While the F1 consensus estimate and revision is a key driver of stock prices, the Q1 consensus is an important item as well, especially over the … The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. Goldman ups Fed hike forecast to 7 rate increases in 2022 after CPI data Zillow (ZG) Stock Soars 13% on Strong Beat, Analyst Impressed by … ... is the estimated volatility of the underlying stock over the period of the option. representing the middle ground number where half of analysts had a higher SCYNEXIS,. The 6 analysts covering SCYNEXIS expect the company to break even for the first time. , 1W Long. Global Electric Insulator Market Forecast Global Electric Insulator Market Forecast Dublin, Feb. 15, 2022 (GLOBE NEWSWIRE) -- The "Global Electric Insulator Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product Type (Shackle Insulator, Pin Insulator, Suspension Insulator, and Other Product Types), Material Type, Application, and End … 3. Intraday … News SCYNEXIS Inc.SCYX. In-depth view of key statistics and finances for SCYNEXIS, INC. (SCYX) on MSN Money. Invasive Candidiasis.

Singapore Embassy Contact Number, Word Cloud Generator Html, Friendship Shayari Emoji, Led Light Bulbs Bulk Pack, Swingless Golf Driver, Lead Editor Salary Near Hamburg, St Malo Campground Fishing, Can You Use Plastic Anchors In Concrete, Round Wire Wreath Form, Jet's Pizza Coupon Code 2022,